Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Ambry's Cancer Panels

Premium

Ambry Genetics has launched four targeted sequencing-based cancer panels: CancerNext, BreastNext, ColoNext, and OvaNext.

The CancerNext panel targets and sequences 23 genes that contribute to increased risk for breast, colon, ovarian, uterine, and other cancers. It excludes the BRCA1 and BRCA2 genes. The test sequences the coding regions of all 23 genes, plus at least 20 bases into the 5' and 3' ends of the introns. Gross deletions and duplications are analyzed for 19 of the genes.

BreastNext, ColoNext, and OvaNext analyze 14, 15, and 20 genes that are specific to breast, colon, and ovarian cancer risk, respectively. Turnaround time is between 70 and 84 days.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.